Aspen’s European Head Thomas Kerscher explains how the sale of the company’s thrombosis portfolio to Mylan has led to an organisational transformation in Europe with a leaner approach and an exclusive focus on anaesthesia. Kerscher also outlines the South African company’s response to the COVID-19 pandemic amid skyrocketing demand for its products.
During the pandemic, it became evident to hospital groups that having a partner that can offer a broad portfolio was a key advantage. We are currently looking at ways to expand our portfolio even further
